Takeda-6d is a dual inhibitor of RAF kinases and VEGFR2.¹It inhibits wild-type B-RAF, mutant B-RAF^V600E, and C-RAF (IC₅₀s = 12, 7, and 1.5 nM, respectively), as well as VEGFR2 (IC₅₀= 2.8 nM). Takeda-6d is selective for these kinases over a panel of 19 additional kinases (IC₅₀s = >1,000 nM) but does inhibit FGFR3, PDGFRα, and PDGFRβ (IC₅₀s = 22, 12, and 5.5 nM, respectively). It inhibits MEK and ERK1/2 phosphorylation in several colon cancer and melanoma cell lines expressing B-RAF^V600Ewhen used at concentrations ranging from 100 to 1,600 nM, as well as inhibits VEGF-A-induced phosphorylation of VEGFR2 in VEGFR2-overexpressing KDR cells (IC₅₀= 0.53 nM). Takeda-6d (10 mg/kg) reduces tumor volume in an A375 melanoma mouse xenograft model.

1.Okaniwa, M., Hirose, M., Imada, T., et al.Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffoldsJ. Med. Chem.55(7)3452-3478(2012)